Market Research Reports and Industry Reports

MITSUBISHI TANABE , Outperform - Invokana: Nice to Have A Clean Label, Yet A Long Way To Go Before Gaining Full Confidence!

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL, CV events observed in first 30 days in CANVAS study), associated genital/UTI infections, compromised efficacy in renally impaired patients and long term safety study requirements by FDA (Table 1), should be seen in conjunction with the clean label. These issues will limit the initial uptake of Invokana to a small segment of diabetic patients - we think patients moving to triple OAD, on GLP-1 or Insulin (due to insufficient control from existing therapies, and escalating disease) are the broader target base of Invokana. Within this broader patient pool, ~40% patients with renal risks, >30% obese patients with co-morbid conditions and CV risks, and females at high UTI infection risk need to be restricted further this leaves a merely ~263k (or ~2.1% of total OAD patients) patients in the US for SGLT-2 inhibitors
Taking All Factors into Account, We arrive the Following Target Patient Base for Invokana (Table 4, 5- Invokana Market Model):.
We expect the market share to split between Invokana: Empagliflozin: Dapagliflozin by ~55:35:10 respectively as
Based on the available data comparision of Empagliflozin vs. Invokana, its efficacy looks better than Empagliflozin. While on safety front, based on PhIIb data empagliflozin reported less genital mycotic infections and equivalent UTI infection to Invokana when indirectly compared.
N/A

List Of Tables

N/A

List Of Figures

N/A

MMC – Mitsubishi Bekasi Vehicle Manufacturing Facility – West Java Project Profile

Synopsis MMC Mitsubishi Bekasi Vehicle Manufacturing Facility West Java Project Profile contains information on the scope of the project including project overview and location. The profile also details project

USD 75View Report

Tenaska/Mitsubishi – Westmoreland Generating Station 925 MW – Pennsylvania Project Profile

Synopsis Tenaska/Mitsubishi Westmoreland Generating Station 925 MW Pennsylvania Project Profile contains information on the scope of the project including project overview and location. The profile also details project

USD 75View Report

Mitsubishi Electric Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Mitsubishi Electric Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Mitsubishi Electric Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350View Report

Mitsubishi Tanabe Pharma Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Mitsubishi Tanabe Pharma Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Mitsubishi Tanabe Pharma Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350View Report

Mitsubishi Tanabe Partnering Deals and Alliances 2010 to 2017

The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the worlds leading life sciences companies.On demand company reports are prepared

USD 1495View Report

Mitsubishi Tanabe Pharma Corp (4508) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, is a pharmaceutical company. The company identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC)

USD 250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 500
  • Site Licence    $ 1000
  • Enterprisewide Licence    $ 1500
$ 500

Reports Details

Published Date : Apr 2013
No. of Pages :9
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop
bostancı escort pendik escort kurtköy escort etiler escort şirinevler escort ankara escort ankara escort bayan escort ankara beylikdüzü escort avcılar escort ankara escort bayan